The Non-Alcoholic Steatohepatitis Biomarkers Market is expanding as demand grows for earlier and less invasive approaches to identifying liver disease. Market Research Future estimates the market at USD 0.19 billion in 2025 and projects it to reach USD 1.94 billion by 2035, representing a 26.19% CAGR.

Advances in biomarker discovery are improving how NASH-related liver damage can be assessed. Research is increasingly exploring serum, hepatic fibrosis, oxidative stress, and apoptosis biomarkers, along with genomic, proteomic, and metabolomic approaches that can support more detailed disease evaluation.

Pharmaceutical companies and CROs represent a major end-user group because biomarkers can support clinical research and drug development. Diagnostic centres, hospitals, clinics, and academic research institutes are also adopting biomarker-based approaches as healthcare systems place greater emphasis on earlier detection and personalized care.

North America currently represents the largest regional market, supported by established healthcare infrastructure, research activity, and investment in liver-disease diagnostics. Asia-Pacific is identified as the fastest-growing region as healthcare spending, disease awareness, and biomarker research expand across major markets.

Future opportunities are centered on non-invasive blood-based tests, improved biomarker validation, and technologies that can help monitor disease progression and treatment response. Greater collaboration among diagnostic companies, pharmaceutical firms, research organizations, and healthcare providers could further accelerate the development and adoption of NASH biomarkers.